Loading
IARC estimates 8,070 new cancer cases and 4,717 cancer deaths in Libya in 2024; the commonest new cancers are trachea, bronchus and lung, breast and colorectum. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 952 | 14.8 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Breast | 913 | 23.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 910 | 13.1 | Colorectal cancer |
| Bladder | 509 | 8.2 | Bladder & urothelial cancer |
| Prostate | 390 | 14.7 | Prostate cancer |
| Cervix uteri | 360 | 9.5 | Cervical cancer |
| Non-Hodgkin lymphoma | 337 | 4.9 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Leukaemia | 328 | 4.9 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Brain, central nervous system | 290 | 4.1 | Glioma & glioblastoma |
| Liver and intrahepatic bile ducts | 282 | 4.5 | Hepatocellular carcinoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 796 | 12.4 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 402 | 5.9 | Colorectal cancer |
| Breast | 331 | 8.7 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Bladder | 285 | 4.7 | Bladder & urothelial cancer |
| Brain, central nervous system | 264 | 3.8 | Glioma & glioblastoma |
| Pancreas | 254 | 3.9 | Pancreatic ductal adenocarcinoma |
| Liver and intrahepatic bile ducts | 250 | 4.0 | Hepatocellular carcinoma |
| Leukaemia | 219 | 3.3 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Stomach | 177 | 2.8 | Gastric & gastro-oesophageal junction cancer |
| Cervix uteri | 172 | 4.6 | Cervical cancer |
No trial record in OnCo lists a site in Libya. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Libya.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Libya is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Libya is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.